Quality by Design for Analytical Methods: Implications for Method Validation and Transfer - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Quality by Design for Analytical Methods: Implications for Method Validation and Transfer
The authors describe how traditional approaches to analytical method and validation may benefit from alignment with quality-by-design concepts.


Pharmaceutical Technology
Volume 36, Issue 10, pp. 74-79

Appendix I

The following examples use risk assessment to determine actions to be taken as part of method performance verification. The aim of the method performance verification exercise is to provide confidence that the modified method will produce results that meet the established criteria defined in the analytical target profile (ATP), which may be assessed by considering each of the method's characteristics and rating the risk that the change in the method will affect each of these characteristics.

Risk assessment tools can be used to provide guidance on what actions are appropriate to verify the method is performing as required.


A1, Table I: Importance of change in column manufacturer for content and impurities by a high-pressure, liquid chromatography method.

A1, Table II: Importance of an increase in column equilibration time prior to next injection for content and impurities by a high-pressure, liquid chromatography method.
The following rating system was used for assessing the possibility of an impact in the two examples of risk assessment shown in A1 Tables I and II:
  • 0 - No possibility of an impact
  • 1 - Very low possibility of an impact
  • 3 - Slight possibility of an impact
  • 5 - Possible impact
  • 7 - Likely impact
  • 9 - Strong likelihood of impact

If a risk to a certain method performance characteristic has been mitigated through other controls (e.g., system suitability), the risk for that characteristic should be reduced accordingly. It should be noted that some methods do not need to be validated for all characteristics; for example, an API assay method may not require sensitivity. In these cases, put a 0 or ''not applicable'' in that category.

Based on the scoring, a decision is made on which characteristics need to be demonstrated (i.e., verified) as meeting the method performance criteria.

For the following examples, any individual score of 5 or above will require work to ensure the suitability of the modified method. Where a score of 5 or above for accuracy is recorded, an equivalence study will be required. Other characteristics that are scored equal to or greater than 5 will require appropriate verification.

Table I shows a risk assessment for a change in the high-pressure, liquid chromatography (HPLC) column manufacturer for a content and impurities method. In this example, the only aspect of the method that is changed is the analytical column manufacturer. The technique has not changed, nor has the basic chemistry driving the technique. The most likely impacts on the reported values for the method are to the selectivity for impurities, which in turn has a potential effect on the accuracy of impurity quantitation. Therefore, for the example situation presented in Table I, it is necessary to assess equivalence between the registered method and modified method for the impurity identification and content. The modified method for impurities should also be verified for selectivity, because the rating for this parameter is greater than or equal to 5. Unless the peak width and/or tailing factor are significantly adversely affected by the change, the sensitivity, precision, and linearity of the method are not likely to be affected by a change in the chromatographic column manufacturer. Moreover, sensitivity and precision are controlled in most methods through the use of system suitability requirements and do not represent a significant risk to the method.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
18%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here